ERCC1 and gastric cancer: Our previous ancillary investigation of another randomized controlled trial, JCOG9912, showed that low ERCC1 expression was a significant independent favorable prognostic factor in patients with advanced gastric cancer who were also receiving first-line chemotherapy.